Results 21 to 30 of about 1,123 (151)

Multiple painful vesicles in a patient with erythroderma [PDF]

open access: yesJAAD Case Reports, 2023
Ricardo Torres-Delgadillo, MD   +4 more
doaj   +2 more sources

Kaposi varicelliform eruption in Darier disease

open access: yesDermatologica Sinica
Yu-Wen Huang   +2 more
doaj   +2 more sources

Severe Eczema Herpeticum With Ocular Involvement Leading to Orbital Cellulitis: A Pediatric Case Report. [PDF]

open access: yesCase Rep Dermatol Med
Eczema herpeticum (EH) is a superimposed cutaneous viral infection that occurs in the context of preexisting dermatoses, most commonly atopic dermatitis (AD). It typically involves the face, neck, and upper trunk. Although ocular involvement is relatively uncommon, it may present diagnostic and therapeutic challenges and pose a significant risk to ...
Chew CH   +3 more
europepmc   +2 more sources

Algorithms in Allergy: Diagnosis and Treatment of Atopic Dermatitis Complicated by Eczema Herpeticum. [PDF]

open access: yesAllergy
Allergy, Volume 80, Issue 8, Page 2417-2420, August 2025.
Traidl S, Heratizadeh A, Werfel T.
europepmc   +2 more sources

Netherton syndrome plus atopic dermatitis: Two new genetic mutations in the same patient. [PDF]

open access: yesClin Case Rep, 2021
Our case is particularly interesting because it clearly highlights the clinical characteristics of a rare disease whose atopic manifestations have been aggravated by a concurrence of FLG2 and SPINK5 mutations. Furthermore, trichoscopy showing invaginated trichoresis could suggest an early diagnosis of Netherton syndrome.
Moar A   +7 more
europepmc   +2 more sources

Infection risk with JAK inhibitors in dermatoses: a meta-analysis. [PDF]

open access: yesInt J Dermatol
Abstract Evolving evidence suggests that Janus Kinase Inhibitors (JAKi) may predispose to certain infections, including tuberculosis and human herpes viruses. This review aimed to compare the infection risk in patients on a systemic JAKi for a dermatologic indication to a placebo.
Ireland PA   +4 more
europepmc   +2 more sources

Plasmapheresis for Facilitating Readministration of Rituximab After Paradoxical Exacerbation in Pemphigus Vulgaris: A Case Report. [PDF]

open access: yesClin Case Rep
ABSTRACT Rare reports of post‐rituximab exacerbation of pemphigus vulgaris (PV) have been published, with some therapeutic protocols proposed for managing this condition. A 40‐year‐old female with PV experienced an exacerbation of mucocutaneous lesions following rituximab administration.
Pourani MR   +4 more
europepmc   +2 more sources

Kaposi varicelliform eruption in a patient with atopic dermatitis

open access: yesJournal of Osteopathic Medicine, 2021
A 23 year old woman with a history of uncontrolled atopic dermatitis presented to the emergency department with an acute onset of a painful papulovesicular facial rash that developed 1 week prior to presentation in September 2020.
Robert P Dazé, J. Canales, R. Ross
semanticscholar   +1 more source

Upadacitinib for moderate‐to‐severe atopic dermatitis: Stratified analysis from three randomized phase 3 trials by key baseline characteristics

open access: yesJournal of the European Academy of Dermatology and Venereology, Volume 37, Issue 9, Page 1871-1880, September 2023., 2023
Abstract Background Atopic dermatitis (AD) is a heterogeneous inflammatory skin disease with different clinical phenotypes based on factors such as age, race, comorbidities, and clinical signs and symptoms. The effect of these factors on therapeutic responses in AD has only been scarcely studied and not for upadacitinib.
J. P. Thyssen   +16 more
wiley   +1 more source

Home - About - Disclaimer - Privacy